β-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus

Clinical Immunology

Volumn 132, Issue 3, 2009, Pages 321-333

  Morshed, Sufi R ^a   Takahashi, Tsuyoshi ^a   Savage, Paul B ^b   Kambham, Neeraja ^a   Strober, Samuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Brigham Young University   (United States)

Author keywords

Innate immunity; NKT cells; Systemic lupus erythematosus; T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BETA GALACTOSYLCERAMIDE; DOUBLE STRANDED DNA ANTIBODY; GALACTOSYLCERAMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD1D; B-LYMPHOCYTES; CERAMIDES; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; KIDNEY; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; MONOSACCHARIDES; NATURAL KILLER T-CELLS; PROTEINURIA; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SPLEEN; SURVIVAL ANALYSIS;

EID: 67651180523     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.05.018     Document Type: Article

References (33)

1. Kotzin B.L. Systemic lupus erythematosus. Cell 85 (1996) 303-306
2. Hahn B.H. Antibodies to DNA. N. Engl. J. Med. 338 (1998) 1359-1368
3. Wofsy D., and Seaman W.E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J. Exp. Med. 161 (1985) 378-391
4. Datta S.K., Patel H., and Berry D. Induction of a cationic shift in IgG anti-DNA autoantibodies. Role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. J. Exp. Med. 165 (1987) 1252-1268
5. Ando D.G., Sercarz E.E., and Hahn B.H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J. Immunol. 138 (1987) 3185-3190
6. Zeng D., Liu Y., Sidobre S., Kronenberg M., and Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 112 (2003) 1211-1222
7. Takahashi T., and Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur. J. Immunol. 38 (2008) 156-165
8. Zeng D., Dick M., Cheng L., Amano M., Dejbakhsh-Jones S., Huie P., Sibley R., and Strober S. Subsets of transgenic T cells that recognize CD1 induce or prevent murine lupus: role of cytokines. J. Exp. Med. 187 (1998) 525-536
9. Ortaldo J.R., Young H.A., Winkler-Pickett R.T., Bere Jr. E.W., Murphy W.J., and Wiltrout R.H. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172 (2004) 943-953
10. Goff R.D., Gao Y., Mattner J., Zhou D., Yin N., Cantu III C., Teyton L., Bendelac A., and Savage P.B., Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 126 (2004) 13602-13603
11. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., and Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
12. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
13. Wilson M.T., Johansson C., Olivares-Villagomez D., Singh A.K., Stanic A.K., Wang C.R., Joyce S., Wick M.J., and Van Kaer L. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad Sci. U. S. A. 100 (2003) 10913-10918
14. Harada M., Seino K., Wakao H., Sakata S., Ishizuka Y., Ito T., Kojo S., Nakayama T., and Taniguchi M. Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation. Int. Immunol. 16 (2004) 241-247
15. Forestier C., Molano A., Im J.S., Dutronc Y., Diamond B., Davidson A., Illarionov P.A., Besra G.S., and Porcelli S.A. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black × New Zealand White)F1 mice. J. Immunol. 175 (2005) 763-770
16. Singh A.K., Yang J.Q., Parekh V.V., Wei J., Wang C.R., Joyce S., Singh R.R., and Van Kaer L. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur. J. Immunol. 35 (2005) 1143-1154
17. Yang J.Q., Saxena V., Xu H., Van Kaer L., Wang C.R., and Singh R.R. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J. Immunol. 171 (2003) 4439-4446
18. Yang J.Q., Singh A.K., Wilson M.T., Satoh M., Stanic A.K., Park J.J., Hong S., Gadola S.D., Mizutani A., Kakumanu S.R., Reeves W.H., Cerundolo V., Joyce S., Van Kaer L., and Singh R.R. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J. Immunol. 171 (2003) 2142-2153
19. Chan O.T., Paliwal V., McNiff J.M., Park S.H., Bendelac A., and Shlomchik M.J. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level. J. Immunol. 167 (2001) 2985-2990
20. Sireci G., Russo D., Dieli F., Porcelli S.A., Taniguchi M., La Manna M.P., Di Liberto D., Scarpa F., and Salerno A. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur. J. Immunol. 37 (2007) 425-433
21. Morshed S.R., Mannoor K., Halder R.C., Kawamura H., Bannai M., Sekikawa H., Watanabe H., and Abo T. Tissue-specific expansion of NKT and CD5+B cells at the onset of autoimmune disease in (NZBxNZW)F1 mice. Eur. J. Immunol. 32 (2002) 2551-2561
22. Parekh V.V., Wilson M.T., Olivares-Villagomez D., Singh A.K., Wu L., Wang C.R., Joyce S., and Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115 (2005) 2572-2583
23. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., Bouillet P., Strasser A., Smyth M.J., and Godfrey D.I. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175 (2005) 3092-3101
24. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., and Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
25. Miyamoto K., Miyake S., and Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 (2001) 531-534
26. Parekh V.V., Singh A.K., Wilson M.T., Olivares-Villagomez D., Bezbradica J.S., Inazawa H., Ehara H., Sakai T., Serizawa I., Wu L., Wang C.R., Joyce S., and Van Kaer L. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J. Immunol. 173 (2004) 3693-3706
27. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., Miura T., Haba T., Scherer D.C., Wei J., Kronenberg M., Koezuka Y., and Van Kaer L. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7 (2001) 1052-1056
28. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., Kronenberg M., Koezuka Y., Delovitch T.L., Gombert J.M., Leite-De-Moraes M., Gouarin C., Zhu R., Hameg A., Nakayama T., Taniguchi M., Lepault F., Lehuen A., Bach J.F., and Herbelin A. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7 (2001) 1057-1062
29. Wang B., Geng Y.B., and Wang C.R. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194 (2001) 313-320
30. Hammond K.J., Poulton L.D., Palmisano L.J., Silveira P.A., Godfrey D.I., and Baxter A.G. alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187 (1998) 1047-1056
31. Lehuen A., Lantz O., Beaudoin L., Laloux V., Carnaud C., Bendelac A., Bach J.F., and Monteiro R.C. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188 (1998) 1831-1839
32. Jahng A.W., Maricic I., Pedersen B., Burdin N., Naidenko O., Kronenberg M., Koezuka Y., and Kumar V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194 (2001) 1789-1799
33. Yang J.Q., Wen X., Liu H., Folayan G., Dong X., Zhou M., Van Kaer L., and Singh R.R. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum. 56 (2007) 1219-1233